Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine

We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anae...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsouli, Olga K., Lainis, Vasileios G., Kapellos, Gerasimos G., Vlachoyiannopoulos, Panayiotis G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201099/
https://www.ncbi.nlm.nih.gov/pubmed/37223596
http://dx.doi.org/10.31138/mjr.34.1.97
_version_ 1785045197032259584
author Katsouli, Olga K.
Lainis, Vasileios G.
Kapellos, Gerasimos G.
Vlachoyiannopoulos, Panayiotis G.
author_facet Katsouli, Olga K.
Lainis, Vasileios G.
Kapellos, Gerasimos G.
Vlachoyiannopoulos, Panayiotis G.
author_sort Katsouli, Olga K.
collection PubMed
description We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anaemia. All the infectious causes were excluded, and immunology tests were negative. Computed Tomography (CT) demonstrated concentric wall thickening of ascending and descending aorta. Positron Emission Tomography (PET) scan showed increased vascular fluorodeoxyglucose (FDG), compatible with LVV. Within one month of treatment with high dose glucocorticoids and iv cyclophosphamide, laboratory findings normalised, and fever resolved.
format Online
Article
Text
id pubmed-10201099
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-102010992023-05-23 Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine Katsouli, Olga K. Lainis, Vasileios G. Kapellos, Gerasimos G. Vlachoyiannopoulos, Panayiotis G. Mediterr J Rheumatol Case Report We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anaemia. All the infectious causes were excluded, and immunology tests were negative. Computed Tomography (CT) demonstrated concentric wall thickening of ascending and descending aorta. Positron Emission Tomography (PET) scan showed increased vascular fluorodeoxyglucose (FDG), compatible with LVV. Within one month of treatment with high dose glucocorticoids and iv cyclophosphamide, laboratory findings normalised, and fever resolved. The Mediterranean Journal of Rheumatology (MJR) 2023-03-31 /pmc/articles/PMC10201099/ /pubmed/37223596 http://dx.doi.org/10.31138/mjr.34.1.97 Text en © 2023 The Mediterranean Journal of Rheumatology (MJR) https://creativecommons.org/licenses/by/4.0/This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Case Report
Katsouli, Olga K.
Lainis, Vasileios G.
Kapellos, Gerasimos G.
Vlachoyiannopoulos, Panayiotis G.
Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title_full Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title_fullStr Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title_full_unstemmed Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title_short Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
title_sort large vessel vasculitis after the administration of oxford-astrazeneca covid-19 vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201099/
https://www.ncbi.nlm.nih.gov/pubmed/37223596
http://dx.doi.org/10.31138/mjr.34.1.97
work_keys_str_mv AT katsouliolgak largevesselvasculitisaftertheadministrationofoxfordastrazenecacovid19vaccine
AT lainisvasileiosg largevesselvasculitisaftertheadministrationofoxfordastrazenecacovid19vaccine
AT kapellosgerasimosg largevesselvasculitisaftertheadministrationofoxfordastrazenecacovid19vaccine
AT vlachoyiannopoulospanayiotisg largevesselvasculitisaftertheadministrationofoxfordastrazenecacovid19vaccine

Ejemplares similares